Synaptogenix announces topline results from nih-sponsored phase 2 clinical trial of bryostatin-1 for advanced alzheimer's disease

New york , dec. 16, 2022 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx) ("synaptogenix" or the "company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced topline data from its national institute of health (nih)-sponsored phase 2 clinical trial of bryostatin-1 for the treatment of advanced alzheimer's disease. the trial's primary endpoint of change from baseline in the severe impairment battery (sib) total score assessment obtained after completion of the second course of treatment (week 28) was not met with statistical significance.
SNPX Ratings Summary
SNPX Quant Ranking